Minerva Neurosciences, Inc. — Q3 2019 Form 10-Q
Business context and reporting period. The filing covers the quarter and nine months ended September 30, 2019. Minerva is a clinical-stage biopharmaceutical company developing CNS candidates, including roluperidone for schizophrenia, seltorexant for insomnia and major depressive disorder (MDD), MIN-117 for MDD, and MIN-301 for Parkinson’s disease. It had no approved products and no product-sale revenue.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $9.7 million (2019); $8.4 million (2018) | $29.6 million (2019); $25.9 million (2018) |
| General and administrative expense | $4.6 million (2019); $4.1 million (2018) | $13.9 million (2019); $12.2 million (2018) |
| Net loss | $14.0 million (2019); $12.0 million (2018) | $42.3 million (2019); $37.0 million (2018) |
| Basic and diluted loss per share | $0.36 (2019); $0.31 (2018) | $1.08 (2019); $0.95 (2018) |
| Net cash used in operating activities | Not provided for the quarter | $29.3 million (2019); $32.1 million (2018) |
Margins are not meaningful because the company reported no revenue. Investment income was $0.3 million for Q3 and $1.2 million for the first nine months of 2019. Interest expense was zero in both 2019 periods.
At September 30, 2019, cash and cash equivalents were $37.9 million, marketable securities $22.0 million, and restricted cash $0.1 million—about $60.0 million combined. Total current assets were $61.4 million; current liabilities were $9.9 million; total assets were $110.8 million and total liabilities $55.3 million. Accumulated deficit was $256.8 million. The company had no borrowings outstanding; its former term loans were repaid in 2018. Deferred revenue was $41.2 million, primarily related to the Janssen collaboration, and is not debt.
Shares outstanding were 39.0 million at September 30 and October 30, 2019. The filing states that available cash, cash equivalents, marketable securities, and restricted cash were expected to fund commitments for at least 12 months after issuance of the interim statements.
Material changes versus the prior comparable periods
- Q3 net loss increased about $1.9 million year over year; nine-month net loss increased about $5.3 million.
- R&D expense rose $1.3 million in Q3 and $3.7 million for nine months, mainly due to roluperidone Phase 3 and MIN-117 Phase 2b development.
- G&A expense rose about $0.5 million in Q3 and $1.7 million for nine months, reflecting higher professional fees and, for the nine-month period, stock-based compensation and salaries.
- Nine-month operating cash use improved by about $2.9 million year over year. Cash, cash equivalents and restricted cash declined $12.3 million during the first nine months of 2019; investing cash inflow largely reflected maturities of marketable securities.
- Operating lease assets and liabilities were recorded following adoption of ASC 842 on January 1, 2019; adoption had no material effect on operations or cash flows.
Outlook, clinical developments and risks
- Roluperidone: 384 patients had enrolled in the Phase 3 trial as of October 1, 2019. A cyber-attack at an external contractor disrupted recruitment; the company expected enrollment to finish around year-end 2019 and top-line 12-week results in the first half of 2020. A long-term commercial supply agreement with Catalent was signed in September 2019.
- MIN-117: Phase 2b enrollment was completed with 360 participants; top-line results were expected in Q4 2019.
- Seltorexant: The company reported positive top-line results from a Phase 2b insomnia trial. In an adjunctive MDD dose-finding trial, the 20 mg dose showed a week-six MADRS difference of 3.1 points versus placebo (two-sided p=0.083, under the trial’s prespecified 0.1 threshold); the 40 mg dose did not reach statistical significance. An exploratory six-month comparison with quetiapine was not powered for statistical significance. Phase 3 plans were not finalized in the filing.
- MIN-301: The company continued preclinical work toward an IND or IMPD filing, with a Phase 1 study expected thereafter.
- Management expects continued operating losses and negative operating cash flows, with R&D and G&A spending expected to increase. The company may need additional capital to fund later-stage development; financing may dilute shareholders or be unavailable on acceptable terms. If funding cannot be obtained, programs could be scaled back or discontinued.
- Clinical outcomes, regulatory approval, commercialization, competition, intellectual-property protection, and dependence on contractors and collaborators are material risks. The filing reported no legal proceedings expected to have a material adverse effect and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether roluperidone enrollment and first-half 2020 results remained on schedule after the contractor cyber-attack.
- MIN-117 Phase 2b top-line results and any resulting development decision.
- Whether Janssen’s seltorexant Phase 3 milestones are triggered, and the timing and terms of any future collaboration funding.
- Cash burn, clinical spending plans, and the assumptions supporting management’s stated minimum 12-month liquidity runway.
- Potential dilution or other financing needs, given recurring losses and the absence of product revenue.